Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 Meeting for AD04
ADIL Stock | USD 0.36 0.01 2.70% |
About 62% of Adial Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Adial Pharmaceuticals suggests that many traders are alarmed regarding Adial Pharmaceuticals' prospects. Adial Pharmaceuticals' investing sentiment shows overall attitude of investors towards Adial Pharmaceuticals.
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use DisorderGLEN ALLEN, Va., Sept. 16, 2025 -- Adial Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced receipt of the final meeting minutes from its End of Ph
Read at finance.yahoo.com
![]() |
Adial Pharmaceuticals Fundamental Analysis
We analyze Adial Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adial Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adial Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Adial Pharmaceuticals is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Adial Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adial Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Adial Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Adial Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Adial Pharmaceuticals Related Equities
SNGX | Soligenix | 6.45 | ||||
VYNE | Vyne Therapeutics | 5.56 | ||||
APRE | Aprea Therapeutics | 1.95 | ||||
MTNB | Matinas BioPharma | 1.75 | ||||
HCWB | HCW Biologics | 0.75 | ||||
BCLI | Brainstorm Cell | 1.37 | ||||
NRSN | Neurosense Therapeutics | 2.46 | ||||
ACXP | Acurx Pharmaceuticals | 3.27 | ||||
BCDA | Biocardia | 7.05 |
Check out Adial Pharmaceuticals Hype Analysis, Adial Pharmaceuticals Correlation and Adial Pharmaceuticals Performance. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.